D956

D956 is a code name for a reference drug used in a clinical trial sponsored by Chong Kun Dang Pharmaceutical. The trial, titled "A Randomized, Open-label, Single Dose, 4-period Replicate Crossover Study to Evaluate the Pharmacokinetic Profiles and Safety of CKD-341 in Healthy Volunteers Under Fasting Conditions," aimed to compare the pharmacokinetic profiles and safety of CKD-341 with D956 in healthy adults. While CKD-341 is being developed as an antihypertensive drug, the specific identity, mechanism of action, and developer of the drug referred to as D956 are not publicly disclosed in the available information. It serves as a comparative agent in the study.